NASDAQ:ZIMV

ZimVie (ZIMV) Stock Price, News & Analysis

$15.81
-0.24 (-1.50%)
(As of 04/24/2024 ET)
Today's Range
$15.69
$16.09
50-Day Range
$15.33
$20.69
52-Week Range
$6.52
$20.91
Volume
117,593 shs
Average Volume
295,950 shs
Market Capitalization
$430.35 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$16.00

ZimVie MarketRank™ Stock Analysis

Analyst Rating
Reduce
1.67 Rating Score
Upside/​Downside
1.2% Upside
$16.00 Price Target
Short Interest
Healthy
3.01% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.06 out of 5 stars

Medical Sector

901st out of 907 stocks

Dental Equipment & Supplies Industry

3rd out of 3 stocks

ZIMV stock logo

About ZimVie Stock (NASDAQ:ZIMV)

ZimVie Inc., together with its subsidiaries, develops, manufactures, and markets a portfolio of products and solutions designed to treat various spine pathologies, and support dental tooth replacement and restoration procedures worldwide. It operates through two segments, The Dental Segment and The Spine Segment. The company offers dental implant systems, prosthetic and abutment products, surgical instrumentation, and kits; and patient-specific restorative solutions, such as abutments, bars, implant bridges, and hybrid restorations under the BellaTek brand name. It provides bone grafts, barrier membranes, and collagen wound care products; virtual treatment planning services, guided surgery solutions, CAD/CAM workflow systems, and intra-oral scanners; and Implant Concierge, a web-based treatment planning and surgery guide service. In addition, the company designs, manufactures, and distributes spinal fusion implants, instrumentation for various spinal procedures, biologics, and bone healing technologies. Further, it provides MIS solutions that deliver implant and instrumentation systems; and motion preservation solutions that offer non-fusion alternatives for cervical disc implant or growth modulation for anterior vertebral body tethering. The company sells its products to oral surgeons, dental specialists, general dentists, dental laboratories, and other dental organizations, including DSOs, as well as educational, medical, and governmental entities, hospitals, and surgery centers through direct sales representatives, agents, and distributors. ZimVie Inc. was incorporated in 2021 and is headquartered in Westminster, Colorado.

ZIMV Stock Price History

ZIMV Stock News Headlines

top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)
AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.
ZimVie Announces Closing of Sale of Spine Business
Multiple Reasons for the Surge of ZimVie (ZIMV) in Q4
top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)
AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.
ZimVie Inc. (ZIMV) Q4 2023 Earnings Call Transcript
Q4 2023 ZimVie Inc Earnings Call
ZimVie Inc. (NASDAQ:ZIMV) Q4 2023 Earnings Call Transcript
Recap: ZimVie Q4 Earnings
What Wall Street expects from ZimVie's earnings
ZIMV Mar 2024 15.000 put
ZIMV Apr 2024 10.000 call
ZIMV Mar 2024 15.000 call
ZimVie: Shrinking Its Way To Profitability
See More Headlines
Receive ZIMV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ZimVie and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/28/2024
Today
4/24/2024
Next Earnings (Estimated)
5/01/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Dental equipment & supplies
Sub-Industry
N/A
Current Symbol
NASDAQ:ZIMV
Fax
N/A
Employees
2,600
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$16.00
High Stock Price Target
$16.00
Low Stock Price Target
$16.00
Potential Upside/Downside
+1.2%
Consensus Rating
Reduce
Rating Score (0-4)
1.67
Research Coverage
3 Analysts

Profitability

Net Income
$-393,280,000.00
Pretax Margin
-11.12%

Debt

Sales & Book Value

Annual Sales
$457.43 million
Cash Flow
$4.91 per share
Book Value
$15.43 per share

Miscellaneous

Free Float
25,855,000
Market Cap
$430.35 million
Optionable
Optionable
Beta
2.18
Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. Vafa Jamali (Age 53)
    President, CEO & Director
    Comp: $1.41M
  • Mr. Richard J. Heppenstall (Age 53)
    Executive VP, CFO & Treasurer
    Comp: $749.83k
  • Mr. Indraneel Kanaglekar (Age 46)
    Senior VP & President of Global Dental
    Comp: $534.5k
  • Ms. Rebecca A. Whitney (Age 47)
    Senior VP & President of Global Spine
    Comp: $622.97k
  • Sandra Schneider
    Chief Accounting Officer
  • Mr. Steve Rondeau
    Senior VP & Chief Information Officer
  • Ms. Heather Kidwell (Age 55)
    Senior VP, Chief Legal, HR & Compliance Officer and Corporate Secretary
    Comp: $460.18k
  • Ms. Laura Driscoll
    Vice President of Communications
  • Ms. Ann Vu
    Senior Vice President of Regulatory Affairs, Quality Assurance & Clinical

ZIMV Stock Analysis - Frequently Asked Questions

Should I buy or sell ZimVie stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ZimVie in the last twelve months. There are currently 1 sell rating and 2 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "reduce" ZIMV shares.
View ZIMV analyst ratings
or view top-rated stocks.

What is ZimVie's stock price target for 2024?

3 Wall Street research analysts have issued 12 month price targets for ZimVie's stock. Their ZIMV share price targets range from $16.00 to $16.00. On average, they predict the company's share price to reach $16.00 in the next twelve months. This suggests a possible upside of 1.2% from the stock's current price.
View analysts price targets for ZIMV
or view top-rated stocks among Wall Street analysts.

How have ZIMV shares performed in 2024?

ZimVie's stock was trading at $17.75 at the start of the year. Since then, ZIMV stock has decreased by 10.9% and is now trading at $15.81.
View the best growth stocks for 2024 here
.

Are investors shorting ZimVie?

ZimVie saw a increase in short interest in March. As of March 31st, there was short interest totaling 788,400 shares, an increase of 21.9% from the March 15th total of 647,000 shares. Based on an average trading volume of 370,300 shares, the days-to-cover ratio is presently 2.1 days. Currently, 3.0% of the company's stock are short sold.
View ZimVie's Short Interest
.

When is ZimVie's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024.
View our ZIMV earnings forecast
.

How were ZimVie's earnings last quarter?

ZimVie Inc. (NASDAQ:ZIMV) posted its quarterly earnings data on Wednesday, February, 28th. The company reported $0.10 earnings per share for the quarter. The company earned $113.07 million during the quarter. ZimVie had a positive trailing twelve-month return on equity of 2.44% and a negative net margin of 51.33%.

What ETF holds ZimVie's stock?

Invesco Russell 2000 Dynamic Multifactor ETF holds 79,950 shares of ZIMV stock, representing 0.36% of its portfolio.

What guidance has ZimVie issued on next quarter's earnings?

ZimVie issued an update on its first quarter 2024 earnings guidance on Wednesday, February, 28th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $115.0 million-$118.0 million.

Who are ZimVie's major shareholders?

ZimVie's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Rice Hall James & Associates LLC (0.65%). Insiders that own company stock include Richard Heppenstall, Sally Crawford and Vafa Jamali.
View institutional ownership trends
.

How do I buy shares of ZimVie?

Shares of ZIMV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ZIMV) was last updated on 4/25/2024 by MarketBeat.com Staff

From Our Partners